These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 32079456)
1. MAFG-AS1 is a novel clinical biomarker for clinical progression and unfavorable prognosis in gastric cancer. Li C; Wu R; Xing Y Cell Cycle; 2020 Mar; 19(5):601-609. PubMed ID: 32079456 [TBL] [Abstract][Full Text] [Related]
2. LncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis. Li D; Zhong S; Zhu Z; Jiang X; Zhang J; Gu J; Chen F Pathobiology; 2020; 87(6):345-355. PubMed ID: 33238264 [TBL] [Abstract][Full Text] [Related]
3. LncRNA MAFG-AS1 Upregulates Polo-Like Kinase-1 by Sponging miR-505 to Promote Gastric Adenocarcinoma Cell Proliferation. Fu Y; Wen J; Li X; Gong M; Guo Z; Wang G Crit Rev Eukaryot Gene Expr; 2021; 31(5):27-32. PubMed ID: 34591387 [TBL] [Abstract][Full Text] [Related]
5. LncRNA MAFG-AS1 is involved in human cancer progression. Li P; Ma X; Gu X Eur J Med Res; 2023 Nov; 28(1):497. PubMed ID: 37941063 [TBL] [Abstract][Full Text] [Related]
6. LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Cui S; Yang X; Zhang L; Zhao Y; Yan W Biochem Biophys Res Commun; 2018 Nov; 506(1):251-258. PubMed ID: 30348529 [TBL] [Abstract][Full Text] [Related]
7. LncRNA MAFG-AS1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/MMP15. Li H; Zhang GY; Pan CH; Zhang XY; Su XY Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2838-2846. PubMed ID: 31002134 [TBL] [Abstract][Full Text] [Related]
8. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15. Jia YC; Wang JY; Liu YY; Li B; Guo H; Zang AM Cell Biol Int; 2019 Apr; 43(4):384-393. PubMed ID: 30599080 [TBL] [Abstract][Full Text] [Related]
9. LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis. Sui Y; Lin G; Zheng Y; Huang W Eur J Pharmacol; 2019 Sep; 859():172465. PubMed ID: 31211984 [TBL] [Abstract][Full Text] [Related]
10. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers. Huang Z; Zhang M; Li J; Lou C Biomed Pharmacother; 2023 Jul; 163():114756. PubMed ID: 37105079 [TBL] [Abstract][Full Text] [Related]
12. Transcription factor ETV1-induced lncRNA MAFG-AS1 promotes migration, invasion, and epithelial-mesenchymal transition of pancreatic cancer cells by recruiting IGF2BP2 to stabilize ETV1 expression. Weng H; Feng W; Li F; Huang D; Lin L; Wang Z Growth Factors; 2023 Aug; 41(3):152-164. PubMed ID: 37428861 [TBL] [Abstract][Full Text] [Related]
13. HBx-upregulated MAFG-AS1 promotes cell proliferation and migration of hepatoma cells by enhancing MAFG expression and stabilizing nonmuscle myosin IIA. Zhang F; Li Y; Gan L; Tong X; Qi D; Wang Q; Ye X FASEB J; 2021 May; 35(5):e21529. PubMed ID: 33813778 [TBL] [Abstract][Full Text] [Related]
14. Carcinogenic roles of MAFG-AS1 in human cancers. Ahmadi M; Morshedzadeh F; Ghaderian SMH; Mousavi P; Habibipour L; Peymani M; Abbaszadegan MR; Ghafouri-Fard S Clin Transl Oncol; 2024 Jan; 26(1):52-68. PubMed ID: 37351806 [TBL] [Abstract][Full Text] [Related]
15. LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1. Bai Y; Ren C; Wang B; Xue J; Li F; Liu J; Yang L Cancer Gene Ther; 2022 Mar; 29(3-4):277-291. PubMed ID: 34035482 [TBL] [Abstract][Full Text] [Related]
16. LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer. Shi XY; Sun YZ; Li M; Li HY Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):232-238. PubMed ID: 31389606 [TBL] [Abstract][Full Text] [Related]
17. High-expression of LncRNA MAFG-AS1 is associated with the prognostic of patients with colorectal cancer. Cui W; Wang Y; Shen X; Wu X; Liu H; Xu X Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1530-1535. PubMed ID: 33295405 [TBL] [Abstract][Full Text] [Related]
18. Increased lncRNA AFAP1-AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer. Feng Y; Zhang Q; Wang J; Liu P Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3842-3849. PubMed ID: 28975981 [TBL] [Abstract][Full Text] [Related]
19. LncRNA ASMTL-AS1/microRNA-1270 differentiate prognostic groups in gastric cancer and influence cell proliferation, migration and invasion. Song Z; Wang J Bioengineered; 2022 Jan; 13(1):1507-1517. PubMed ID: 34986743 [TBL] [Abstract][Full Text] [Related]
20. Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer. Zhang W; Huang L; Lu X; Wang K; Ning X; Liu Z Bosn J Basic Med Sci; 2019 May; 19(2):164-171. PubMed ID: 30821221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]